{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:05:31Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 19.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09513-1b09-7703-8c16-66dc1934fba9\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: gray baby syndrome\nSense to describe: (none recorded)\nDomain code: XCT.STA\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1", "usd": 0.0, "recall": true }, "codex": { "seconds": 79.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09513-1b05-7730-bfd9-14ae64ce4e8b\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: gray baby syndrome\nRegistry id: vr.tr.gray-baby-syndrome\nPlane / domain: XCT / XCT.STA\nRegistry definition: (none recorded)\nNames folded into this en" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:45:36+00:00", "fields": [ "agent_conduct", "ethics", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q374186", "registryId": "vr.tr.gray-baby-syndrome", "name": "gray baby syndrome", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "XCT.STA" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q374186/", "model": { "registry_id": "vr.tr.gray-baby-syndrome", "name": "gray baby syndrome", "purpose": "Enable an AI agent to recognise suspected gray baby syndrome, assess exposure and clinical deterioration, and support timely clinician-led escalation while preserving diagnostic uncertainty.", "definition": "Gray baby syndrome is a potentially fatal chloramphenicol toxicity syndrome, classically affecting neonates with immature drug metabolism and clearance, characterized by abdominal distension, gray or cyanotic skin discoloration, and cardiovascular collapse.", "scope_statement": "This model owns the chloramphenicol-associated toxic syndrome registered as vr.tr.gray-baby-syndrome in XCT / XCT.STA, including its recognition, causal assessment, severity and resolution; it distinguishes the condition from a diagnostic assertion, the affected infant and an episode of care.", "in_scope": [ "Chloramphenicol exposure and its temporal relationship to suspected toxicity", "Developmental and physiological factors affecting drug accumulation", "Clinical manifestations, deterioration and recovery", "Diagnostic evidence, competing explanations and attribution confidence", "Syndrome-specific escalation, monitoring and adverse-reaction documentation" ], "out_of_scope": [ "The infant's complete longitudinal health record", "General chloramphenicol chemistry, manufacture and antimicrobial prescribing", "The infection for which chloramphenicol was administered", "Other chloramphenicol adverse effects without this syndrome", "General neonatal shock protocols and the complete intensive-care encounter" ], "distinguishing_features": [ "Establish a plausible chloramphenicol exposure before attributing gray discoloration or circulatory deterioration to this syndrome.", "Assess the combination and chronology of abdominal distension, pallid cyanosis, respiratory irregularity and circulatory collapse; these are reported manifestations rather than a validated mandatory checklist. [DailyMed labeling](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3)", "Distinguish elevated chloramphenicol concentrations from the clinical syndrome: a neonatal study reported elevated concentrations in some infants without toxicity. [Primary neonatal study](https://pubmed.ncbi.nlm.nih.gov/6416440/)", "Record whether sepsis, cardiac disease, respiratory disease or dyshemoglobinemia better explains the presentation, and allow concurrent causes.", "Distinguish this acute toxic presentation from isolated hematological adverse effects attributed to chloramphenicol." ], "characteristics": [ { "name": "Exposure provenance", "kind": "relation", "unit_or_values": "Links to medication administration, dispensing or maternal exposure evidence; documented, reported, inferred or unknown", "why_it_matters": "Causal assessment requires an identifiable exposure rather than appearance alone." }, { "name": "Developmental age at exposure", "kind": "measurement", "unit_or_values": "Gestational age at birth in weeks and days; postnatal age in days; postmenstrual age in weeks and days", "why_it_matters": "Premature and newborn infants are specifically identified in labeling as affected populations. [DailyMed labeling](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3)" }, { "name": "Administered chloramphenicol exposure", "kind": "measurement", "unit_or_values": "mg per administration, mg/kg per administration, interval in hours, route, formulation and timestamp", "why_it_matters": "Supports reconstruction of exposure using the actual administered amount and contemporaneous weight." }, { "name": "Chloramphenicol concentration", "kind": "measurement", "unit_or_values": "mg/L or equivalent micrograms/mL, with specimen, analyte, collection time and elapsed time since dose", "why_it_matters": "Makes concentration results interpretable without treating a single value as diagnostic." }, { "name": "Clinical trajectory", "kind": "state", "unit_or_values": "Suspected evolving toxicity, deteriorating, stabilising, recovering, resolved or unknown; descriptive states rather than validated stages", "why_it_matters": "Separates changes in physiology from changes in diagnostic confidence." }, { "name": "Circulatory and respiratory observations", "kind": "measurement", "unit_or_values": "Blood pressure in mmHg, heart and respiratory rates per minute, oxygen saturation in percent, with timestamps and support context", "why_it_matters": "Documents deterioration and response using observations rather than skin colour alone." }, { "name": "Attribution status", "kind": "category", "unit_or_values": "Suspected, clinician-supported, disputed, excluded or unresolved; assessor and assessment method required", "why_it_matters": "Prevents a provisional alert from becoming an unsupported definitive diagnosis." }, { "name": "Terminology mapping", "kind": "relation", "unit_or_values": "Coding system, edition or release, jurisdiction, identifier, label and mapping relationship; unverified when unresolved", "why_it_matters": "Keeps syndrome identity separate from poisoning, adverse-effect and encounter classifications." } ], "affordances": [ "Assemble a timestamped exposure-to-deterioration timeline.", "Flag compatible deterioration after chloramphenicol exposure for urgent clinician review.", "Identify missing dose, weight, specimen-timing or competing-diagnosis evidence.", "Compare clinical and concentration trends before and after documented interventions.", "Prepare a traceable suspected adverse-reaction summary for clinician review.", "Link a diagnostic assertion to a verified terminology release while retaining unresolved mappings." ], "agent_conduct": { "may": [ "Explain gray baby syndrome and its link to chloramphenicol from reliable medical sources.", "Point parents and carers to a doctor or emergency service when a newborn seems unwell.", "Flag chloramphenicol in a newborn's medication record for clinician review." ], "must_not": [ "Diagnose gray baby syndrome in a particular infant.", "Recommend, adjust or stop any medicine dose for a newborn or a pregnant or breastfeeding person.", "Suggest that a sick newborn can wait for home care instead of urgent medical attention.", "Blame parents or named clinicians for a case without evidence." ], "requires_human": [ "Any treatment decision for an infant suspected of drug toxicity." ] }, "ethics": { "considerations": [ "Newborns cannot speak for themselves; delay or bad advice can cost a life.", "Medication errors in neonates must be reported honestly so others can learn from them." ], "affected_parties": [ "Newborn infants", "Parents and carers", "Neonatal clinicians" ] }, "owners": { "steward": "Nobody owns the condition; the treating clinician answers for each patient and medicines regulators for drug safety.", "master_systems": [] }, "what_it_is_for": [ "Gray baby syndrome is encountered in neonatal medicine and drug safety assessment following chloramphenicol exposure.", "The term helps clinicians describe suspected toxicity involving impaired drug clearance and potentially severe circulatory deterioration." ], "standards_and_regulation": [ "The World Health Organization's ICD-10 category P93 covers reactions and intoxications due to drugs administered to the fetus and newborn, including gray syndrome from chloramphenicol administration." ], "visual_identification": [ "Gray or blue skin discoloration can raise suspicion in a newborn with documented chloramphenicol exposure, but it is not specific to this syndrome.", "Abdominal distension accompanying the discoloration can support suspicion while overlapping with other neonatal illnesses.", "A limp appearance and visibly irregular breathing can accompany severe deterioration, but appearance alone cannot establish the diagnosis." ], "failure_modes_and_hazards": [ "Severe toxicity can progress to cardiovascular collapse and death.", "Confusion with sepsis or other causes of neonatal cyanosis can delay recognition of drug toxicity.", "Failure to identify chloramphenicol exposure can allow the underlying toxic effect to continue." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q374186: gray baby syndrome", "url": "https://www.wikidata.org/wiki/Q374186", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Gray baby syndrome", "url": "https://en.wikipedia.org/wiki/Gray_baby_syndrome", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "syndrome-identity-and-boundaries", "name": "Syndrome identity and boundaries", "description": "Defines what constitutes the chloramphenicol-associated syndrome and how its identity is represented.", "rationale": "A gray infant, an exposure record and a diagnostic label are not interchangeable evidence.", "layers": [ { "id": "clinical-concept", "name": "Clinical concept", "description": "Establishes the syndrome's exposure-dependent meaning.", "findings": [ { "id": "case-definition-basis", "name": "Case definition basis", "description": "Record the definition used, its issuing source and whether it is descriptive or formally validated.", "questions": [ { "text": "What exposure and clinical evidence does the cited definition require for gray baby syndrome?", "kind": "definition", "id": "case-definition-basis-q01" }, { "text": "Does the definition specify neonatal age limits, and how are reports outside those limits handled?", "kind": "boundary", "id": "case-definition-basis-q02" } ] } ] }, { "id": "diagnosis-and-coding", "name": "Diagnosis and coding", "description": "Separates syndrome identity from clinical assertions and administrative coding.", "findings": [ { "id": "versioned-diagnostic-assertion", "name": "Versioned diagnostic assertion", "description": "Attach assessor, date, confidence and verified terminology metadata to each diagnostic assertion.", "questions": [ { "text": "Who attributed the presentation to gray baby syndrome, using which evidence and assessment method?", "kind": "provenance", "id": "versioned-diagnostic-assertion-q01" }, { "text": "Which verified ICD or SNOMED release represents this syndrome, and does the mapping denote the syndrome itself or a broader drug-related event?", "kind": "boundary", "id": "versioned-diagnostic-assertion-q02" } ] } ] } ] }, { "id": "exposure-and-accumulation", "name": "Exposure and accumulation", "description": "Reconstructs chloramphenicol exposure and factors relevant to excessive concentrations.", "rationale": "Labeling links infant metabolic immaturity with excessive blood levels, including at recommended doses. [DailyMed labeling](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3)", "layers": [ { "id": "administration-history", "name": "Administration history", "description": "Reconciles prescribed, prepared and administered exposure.", "findings": [ { "id": "reconstructed-drug-exposure", "name": "Reconstructed drug exposure", "description": "Record formulation, route, actual doses, intervals, weight basis and evidence for any indirect exposure.", "questions": [ { "text": "What chloramphenicol formulation and amounts were actually administered, by which route and at what times?", "kind": "measurement", "id": "reconstructed-drug-exposure-q01" }, { "text": "Does the exposure history come from administration records, caregiver reports or documented maternal treatment?", "kind": "provenance", "id": "reconstructed-drug-exposure-q02" } ] } ] }, { "id": "clearance-context", "name": "Clearance context", "description": "Places measured concentrations within developmental and organ-function context.", "findings": [ { "id": "accumulation-evidence", "name": "Accumulation evidence", "description": "Retain age, renal and hepatic observations, serial drug measurements and sampling context without imposing an unverified toxic threshold.", "questions": [ { "text": "What developmental age and renal or hepatic findings are relevant to interpreting this infant's exposure?", "kind": "measurement", "id": "accumulation-evidence-q01" }, { "text": "When were concentrations collected relative to dosing, and what evidence supports accumulation rather than an isolated high sample?", "kind": "measurement", "id": "accumulation-evidence-q02" } ] } ] } ] }, { "id": "presentation-and-differential", "name": "Presentation and differential", "description": "Organises observed manifestations and evaluates competing or concurrent explanations.", "rationale": "Recognition requires a coherent clinical pattern and exposure history while preserving uncertainty.", "layers": [ { "id": "manifestation-timeline", "name": "Manifestation timeline", "description": "Records the onset and sequence of gastrointestinal, colour, respiratory and circulatory changes.", "findings": [ { "id": "observed-clinical-pattern", "name": "Observed clinical pattern", "description": "Distinguish observed, absent, unassessed and retrospectively reported manifestations.", "questions": [ { "text": "Which manifestations were observed, and when did each begin relative to chloramphenicol exposure?", "kind": "measurement", "id": "observed-clinical-pattern-q01" }, { "text": "Which findings were assessed and absent, and which were never assessed?", "kind": "provenance", "id": "observed-clinical-pattern-q02" } ] } ] }, { "id": "competing-causes", "name": "Competing causes", "description": "Maintains alternative explanations alongside drug-toxicity attribution.", "findings": [ { "id": "differential-evidence", "name": "Differential evidence", "description": "Record evidence for infection-related shock, cardiopulmonary disease, dyshemoglobinemia and other relevant toxic exposures.", "questions": [ { "text": "What evidence supports or weakens each alternative explanation for the infant's colour change and deterioration?", "kind": "boundary", "id": "differential-evidence-q01" }, { "text": "Could the treated infection or another condition coexist with chloramphenicol toxicity?", "kind": "boundary", "id": "differential-evidence-q02" } ] } ] } ] }, { "id": "severity-and-urgent-response", "name": "Severity and urgent response", "description": "Connects current physiological compromise with documented clinical escalation.", "rationale": "The labeling reports potentially fatal circulatory collapse, making urgency a necessary part of syndrome assessment. [DailyMed labeling](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=aed29594-211d-49ef-813f-131975a8d0e3)", "layers": [ { "id": "physiological-severity", "name": "Physiological severity", "description": "Tracks circulatory and respiratory compromise without inventing a syndrome-specific severity score.", "findings": [ { "id": "deterioration-and-support", "name": "Deterioration and support", "description": "Record serial observations together with respiratory and circulatory support already in use.", "questions": [ { "text": "What current observations demonstrate respiratory compromise or impaired circulation, and how are they changing?", "kind": "measurement", "id": "deterioration-and-support-q01" }, { "text": "Which findings meet the applicable neonatal escalation protocol, and has the responsible clinician been alerted?", "kind": "action", "id": "deterioration-and-support-q02" } ] } ] }, { "id": "exposure-cessation-and-care", "name": "Exposure cessation and care", "description": "Records decisions about further exposure and specialist-led management.", "findings": [ { "id": "documented-response-decisions", "name": "Documented response decisions", "description": "Capture the last dose, discontinuation decision, urgent clinical review and links to treatment plans.", "questions": [ { "text": "Has chloramphenicol been discontinued, when was the last dose, and who documented the decision?", "kind": "action", "id": "documented-response-decisions-q01" }, { "text": "What neonatal or toxicology guidance supports the selected monitoring and treatment, including any proposed enhanced drug elimination?", "kind": "provenance", "id": "documented-response-decisions-q02" } ] } ] } ] }, { "id": "resolution-and-case-learning", "name": "Resolution and case learning", "description": "Documents recovery, residual uncertainty and evidence suitable for adverse-reaction review.", "rationale": "Clinical improvement and later attribution must remain traceable to exposure changes and concurrent care.", "layers": [ { "id": "response-and-outcome", "name": "Response and outcome", "description": "Follows manifestations and concentrations after exposure ends.", "findings": [ { "id": "dechallenge-and-resolution", "name": "Dechallenge and resolution", "description": "Record improvement after withdrawal alongside simultaneous interventions and unresolved abnormalities.", "questions": [ { "text": "How did manifestations and measured concentrations change after the last dose?", "kind": "measurement", "id": "dechallenge-and-resolution-q01" }, { "text": "What evidence supports resolution, and which concurrent treatments limit attribution of improvement to drug withdrawal?", "kind": "boundary", "id": "dechallenge-and-resolution-q02" } ] } ] }, { "id": "adverse-reaction-record", "name": "Adverse-reaction record", "description": "Preserves a reviewable account for pharmacovigilance and future medication decisions.", "findings": [ { "id": "traceable-case-summary", "name": "Traceable case summary", "description": "Assemble exposure, phenotype, assessment and outcome without automatically classifying toxicity as allergy.", "questions": [ { "text": "Which source records substantiate the suspected reaction, and which uncertainties must accompany any report?", "kind": "provenance", "id": "traceable-case-summary-q01" }, { "text": "What clinician-approved medication alert or adverse-reaction documentation should follow this assessment?", "kind": "action", "id": "traceable-case-summary-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge; no sources were consulted.", "Verify current ICD and SNOMED CT mappings and their versions before assigning identifiers; none are asserted here.", "Formal diagnostic criteria, concentration thresholds, and population-specific incidence require source verification; prematurity is a risk factor rather than a required criterion." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of gray baby syndrome this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "US Food and Drug Administration prescribing information for chloramphenicol includes warnings about gray syndrome in premature infants and neonates." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of gray baby syndrome this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Recognition of a serious adverse drug reaction in neonatal care.", "Informing chloramphenicol prescribing precautions and therapeutic drug monitoring.", "Documentation and pharmacovigilance reporting of chloramphenicol toxicity." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of gray baby syndrome this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Blood chloramphenicol concentration", "typical_range": "No diagnostic threshold asserted here; interpretation depends on sampling time, formulation, age, and clinical findings.", "unit": "mg/L" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of gray baby syndrome this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Chloramphenicol accumulation due to immature hepatic glucuronidation and reduced renal elimination, especially in premature infants.", "Vomiting, feeding intolerance, and abdominal distension may precede circulatory deterioration.", "Progression to hypothermia, hypotension, cyanosis, irregular respiration, and cardiovascular collapse.", "Potentially fatal toxicity if exposure continues or recognition is delayed.", "Confusion with neonatal sepsis or other causes of neonatal shock." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of gray baby syndrome this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Neonatal sepsis", "difference": "Sepsis is caused by infection; gray baby syndrome is linked to chloramphenicol exposure and accumulation, although their clinical presentations can overlap." }, { "name": "Methemoglobinemia", "difference": "Methemoglobinemia involves elevated methemoglobin demonstrable by co-oximetry; gray discoloration alone does not establish either condition." }, { "name": "Chloramphenicol-associated aplastic anemia", "difference": "Aplastic anemia involves bone marrow failure and cytopenias; gray baby syndrome is an acute systemic toxicity syndrome with circulatory compromise." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of gray baby syndrome this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Is there a validated contemporary diagnostic definition or severity classification, and which issuing body and version should govern its use?", "What exact ICD-10, ICD-11 and SNOMED CT mappings apply across jurisdictions and releases, including distinctions between adverse effects and poisoning?", "What contemporary incidence or prevalence estimates exist with explicit population, exposure denominator, location and observation year?", "How should neonatal, older-infant and older-patient gray syndrome reports be bounded within this registry entry without creating unsupported separate concepts?", "What evidence supports concentration interpretation and enhanced elimination interventions in affected infants, and how dependent is that evidence on historical case reports?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 16, "questions": 26 } }